NCT00125879View on ClinicalTrials.gov

Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

December 31, 2006

Conditions
Glycogen Storage Disease Type II
Interventions
BIOLOGICAL

Myozyme

20 mg/kg qow or 40 mg/kg qow

Trial Locations (14)

710

Chi-Mei Medical Center Dept of Pediatrics, Tainan City

970

Tzu-Chi General Hospital, Hualien City

14033

CHU Cote de Nacre, Caen

20052

San Gerardo Hospital, Monza

27710

Duke University Medical Center, Durham

30033

Emory University Medical Genetics, Decatur

32610

Shands Hospital at the University of Florida, Gainesville

33155

Miami Children's Hospital, Miami

35233

University of Alabama, Birmingham

35254

Rambam Medical Center, Haifa

45229

Children's Hospital Medical Center, Cincinnati

55131

Universitats-Kinderklinik Mainz, Mainz

80054

CHU Amiens, Amiens

3015 GJ

Erasmus MC University, Rotterdam

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00125879 - Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602 | Biotech Hunter | Biotech Hunter